112 related articles for article (PubMed ID: 9491207)
1. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer.
Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G
Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207
[TBL] [Abstract][Full Text] [Related]
2. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
Wang ZP; Zheng RL; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
[TBL] [Abstract][Full Text] [Related]
3. Modulating effect of mitomycin or cisplatin on lymphokine-activated killer cell proliferation and antitumor activity to bladder cancer cell lines in vitro.
Wang ZP; Qing DS; Shi BG; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):369-72. PubMed ID: 10375787
[TBL] [Abstract][Full Text] [Related]
4. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
[TBL] [Abstract][Full Text] [Related]
5. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
6. Basic fibroblast growth factor enhanced LAK cell cytotoxicities against human bladder neoplasm cells.
Wang ZP; Duan GL; Chen YR; Qin DS; Liu GD; Niu HG
Zhongguo Yao Li Xue Bao; 1999 Mar; 20(3):276-8. PubMed ID: 10452107
[TBL] [Abstract][Full Text] [Related]
7. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
8. The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.
Chao TY; Ting CS; Chu TM; Yeh MY
Proc Natl Sci Counc Repub China B; 1993 Oct; 17(4):138-42. PubMed ID: 8171164
[TBL] [Abstract][Full Text] [Related]
9. Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients.
Chao TY; Ting CS; Yeh MY; Chang JY; Wang CC; Chu TM
Tumour Biol; 1995; 16(4):230-42. PubMed ID: 7604204
[TBL] [Abstract][Full Text] [Related]
10. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
11. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
12. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.
Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD
J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
14. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
15. The relative resistance of lymphokine activated killer cells to suppression by prostaglandins and glucocorticoids.
Imir T; Sibbitt W; Bankhurst A
Prostaglandins Leukot Med; 1987 Jul; 28(2):111-8. PubMed ID: 3498171
[TBL] [Abstract][Full Text] [Related]
16. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.
Ohnishi H; Lin TH; Nakajima I; Chu TM
Tumour Biol; 1991; 12(2):99-110. PubMed ID: 2028183
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
[TBL] [Abstract][Full Text] [Related]
19. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
Yamamoto K; Tanaka R; Yoshida S; Ono K; Mori H; Taniguchi Y; Oda T; Watanabe T
J Immunother; 1999 Jan; 22(1):33-40. PubMed ID: 9924697
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
